Oncotarget

Research Papers:

Hypoxia primes human normal prostate epithelial cells and cancer cell lines for the NLRP3 and AIM2 inflammasome activation

Ravichandran Panchanathan, Hongzhu Liu and Divaker Choubey _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:28183-28194. https://doi.org/10.18632/oncotarget.8594

Metrics: PDF 2392 views  |   HTML 2854 views  |   ?  


Abstract

Ravichandran Panchanathan1,2, Hongzhu Liu1,2, Divaker Choubey1,2

1Cincinnati VA Medical Center, Cincinnati, OH 45220, USA

2Department of Environmental Health, University of Cincinnati, Cincinnati, OH 45267, USA

Correspondence to:

Divaker Choubey, email: [email protected]

Keywords: hypoxia, prostate, inflammasome, inflammation, cancer

Received: December 15, 2015     Accepted: March 28, 2016     Published: April 5, 2016

ABSTRACT

The molecular mechanisms by which hypoxia contributes to prostatic chronic inflammation (PCI) remain largely unknown. Because hypoxia stimulates the transcriptional activity of NF-κB, which “primes” cells for inflammasome activation by inducing the expression of NLRP3 or AIM2 receptor and pro-IL-1β, we investigated whether hypoxia could activate the NLRP3 and AIM2 inflammasome in human normal prostate epithelial cells (PrECs) and cancer cell lines. Here we report that hypoxia (1% O2) treatment of PrECs, prostate cell lines, and a macrophage cell line (THP-1) increased the levels of NLRP3, AIM2, and pro-IL-1β. Further, hypoxia in cells potentiated activation of the NLRP3 and AIM2 inflammasome activity. Notably, hypoxia “primed” cells for NLRP3 and AIM2 inflammasome activation through stimulation of the NF-κB activity. Our observations support the idea that hypoxia in human prostatic tumors contributes to PCI, in part, by priming cells for the activation of NLRP3 and AIM2 inflammasome.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8594